Wound Care Biologics Market

Wound Care Biologics Market Outlook (2022-2032)

The global wound care biologics market is currently valued at US$ 2.09 billion. Worldwide demand for wound care biologics is predicted to rise at a high-value CAGR of 11% and reach US$ 5.93 billion by the end of 2032.

Wound care biologics products are further classified into biological skin substitutes and topical agents. Sales of biological skin substitutes are expected to increase at a CAGR of 11.5% during the forecast period.

Biological skin substitutes are a diverse range of materials used for wound closure. Patients with severe burns are primarily treated using biological skin substitutes. The biological skin substitutes also enable the development of a more natural new dermis, ensuring that wounds heal quickly.

Sales of biologic skin substitutes are expected to be primarily driven by the increasing number of burn injuries and chronic wounds. Chronic wounds may further lead to severe infections, ulcers, and insufficient blood flow.

• According to a study titled "The Role of Advanced Biologics (Skin Substitutes) in Wound Healing" that was published in The Wound Docs in December 2021, inexpensive, easily accessible biological skin substitutes allow for considerable re-epithelialization. The most often utilised biological skin substitutes are cadaver allografts, amnion, and porcine skin xenografts.

For the treatment of chronic injuries, such as diabetic foot ulcers and venous ulcers, as well as burn injuries, and injuries sustained in auto accidents, biological skin substitutes are strongly advised.

New developments in skin tissue engineering such as the use of 3D printers have increased its acceptance among surgeons, driving up the demand for biological skin substitutes. One of the helpful instruments in reconstructive surgical procedures that are frequently utilised as an alternative to skin grafts is biological skin substitutes.

For breast reconstruction surgeries, an allogenic acellular dermal matrix is highly preferred. Furthermore, products made of an acellular dermal matrix are used to treat diabetic lower extremity ulcers. The sales growth would be driven by the high employment of such excellent biological skin substitutes in aesthetic operations during the forecast period.

• For instance, Integra LifeSciences introduced the Amnio Excel Plus Placental Allograft Membrane in February 2020. It helps soft tissue repair and is their latest solution in terms of biological wound healing treatment.
• A novel placental membrane-based product called Enverse, used for acute and chronic wounds, was also introduced in July 2022 by StimLabs, LLC, a pioneer in regenerative technologies and solutions that are redefining patient care via innovation and individualized solutions.

The use of cotton gins for wound management dates back to 1793, marking the beginning of the wound care biologics sector. The wound care biologics business has undergone tremendous change since then.

As antiseptic dressings offered quicker wound healing with minimal microbial activity, they eventually supplanted the standard bandages that were previously available. Currently, due to advancements in research and studies, topical agents and biotechnologically created skin have revolutionized the wound healing process, making it more convenient and simple.

Hemostasis, inflammation, proliferation, and remodelling are all important biological processes that take place during wound healing. Several different cell types, such as neutrophils, lymphocytes, macrophages, fibroblasts, keratinocytes, and endothelial cells, are heavily involved in this process.

Technological advancements, rising cases of chronic illness, an increase in accidents and trauma, and a rise in the number of elderly people with chronic wound diseases such as diabetes are all contributing to the rising demand for wound biologics.

Report Attributes	Details
Wound Care Biologics Market Size (2022E)	US$ 2.09 Billion
Forecasted Market Value (2032F)	US$ 5.93 Billion
Global Market Growth Rate (2022-2032)	11% CAGR
China Market Growth Rate (2022-2032)	16% CAGR
Key Companies Profiled	Acell Anika Therapeutics Integra Lifesciences Kerecis Marine Polymer Technologies Mimedx Group Mölnlycke Health Care AB (Investor AB) Organogenesis Osiris Therapeutics Smith & Nephew

What are the Demand Growth Drivers for Wound Care Biologics Products?

“Growing Cases of Burn Injuries Worldwide”

The growth of the wound care biologics market will be positively impacted by the rising number of burn injuries, particularly in developing and underdeveloped nations. There are many cases of burns in nations such as Brazil and Africa.

• For instance, the WHO estimates that each year in low- and middle-income countries, burns account for over 180,000 fatalities.

Burns have terrible consequences on the victim's skin in addition to significant financial consequences. Also, there are various treatment methods for burns, which are categorised based on the severity of the injury.

One of the most popular treatments for burns is wound care biologics since it promotes a quick recovery with few to no complications. Therefore, the availability of high-quality synthetic replacements and the rising demand for them in the treatment of burns have been advantageous for the industry's development.

“Rising Prevalence of Diabetic Foot Ulcers”

Since diabetic individuals are more likely to develop diabetic ulcers, the demand for wound care biologics is expected to increase significantly as diabetes incidence increases globally.

• For instance, the prevalence of diabetes is rising across the globe, primarily as a result of obesity, a poor diet, and a lack of exercise.
• A study titled "Diabetic Foot Ulcer" which was published in the National Library of Medicine in May 2022 estimates that there are between 9.1 and 26.1 million diabetic foot ulcers each year throughout the world.

A diabetic foot ulcer has been experienced by 15% to 25% of patients with diabetes mellitus at some time in their lives. The prevalence of diabetic foot ulcers will inevitably increase as more people are diagnosed with the disease each year worldwide. Therefore, demand for wound care biologics is anticipated to rise during the forecast period.

What Could Possibly Stunt Demand for Wound Care Biologics Treatment?

“High Cost of Treatment & Risk of Treatment Failure”

It is anticipated that the high cost of wound care biologics and wound treatment will impede sales growth. The risk of skin substitute failure is anticipated to pose an obstacle to wound care biologics manufacturers throughout the forecast period.

Which Regional Market is Considered Lucrative for Wound Care Biologics Treatment Providers?

“Rise in Traffic Accidents & Presence of Advanced Healthcare Infrastructure in North America”

The market in North America is predicted to be driven by an increase in traffic accidents, a rise in the cases of chronic diseases, and the existence of numerous major competitors in the region.

During the projected period, this demand is also expected to be influenced by advancements in healthcare infrastructure and the presence of skilled medical experts.

Over the forecast period, the Asia Pacific market is anticipated to experience the quickest development. It is projected that the prominence of the major marketplace such as China, India, South Korea, and Japan will accelerate sales growth in the Asia Pacific region. Furthermore, the prevalence of chronic diseases, particularly diabetes, is predicted to boost sales of wound care biologics.

Country-wise Analysis

How is Demand for Wound Care Biologics Treatment Expected to Shape Up in the U.S.?

“Aesthetic Operations Highly Popular in Nation”

Increasing prevalence of diabetic foot ulcers can be ascribed to the high sales growth of wound care biologics.

• About 10% of diabetic patients experience chronic foot ulcers, according to Azura Vascular Care.

Diabetes patients' bodies don't get enough oxygen, which slows down wound healing and makes them more vulnerable to bacterial and fungal skin conditions.

Moreover, during the anticipated period, the demand for biological skin substitutes in aesthetic operations would boost the growth of the U.S. wound care biologics market.

What is Supporting Sales of Wound Care Biologics in European Countries?

“Growing Awareness of Advanced Wound Care Treatment & High Prevalence of Gestational Diabetes”

In European nations such as the U.K., Spain, France, and Germany, growing awareness of advanced wound care treatment products is anticipated to generate lucrative growth prospects.

There is a belief that factors such as rising obesity and lack of exercise are contributing to the prevalence of diabetes.

In addition to diabetes, breast cancer is becoming more common in the UK. There is a significant demand for advanced wound care treatment in the nation due to the increase in frequency and complexity of breast surgical operations.

In Germany, there is a high prevalence of gestational diabetes in women. Thus, it is anticipated that the aforementioned factors will increase the sales of biologics for wound care in European nations.

Category-wise Analysis

Which Wound Type Accounts for High Demand for Wound Care Biologics?

“Burns & Other Acute Wounds Most Common Across Globe”

Wound care biologics are typically used to treat wounds such as ulcers, surgical & traumatic wounds, and burns.

Burns and other acute wounds, such as surgical and traumatic wounds, are quite common around the world. There is high demand for wound care biologics due to rising cases of diabetes wounds, across the globe.

Diabetes wounds are caused due to excessive blood sugar levels, which frequently result in hormonal imbalance and diseases such as chronic foot ulcers.

• According to OxyGeneration, at least 15% to 20% of patients with diabetes will develop foot ulcers.

Clinical professionals typically favour biologics for wound treatment that promote a suitable environment for healing.

Demand for wound care biologics will increase as pressure ulcer wounds such as bed sores become more common. Additionally, the presence of significant side effects such as cellulites, bacteremia, sepsis, and septic arthritis in patients with pressure ulcers increases the sales of wound care biologics.

Competitive Landscape

Key players in the wound care biologics market are Acell, Anika Therapeutics, Integra Lifesciences, Kerecis, Marine Polymer Technologies, Mimedx Group, Mölnlycke Health Care AB (Investor AB), Organogenesis, Osiris Therapeutics, and Smith & Nephew.

Sales will rise over the coming years as a result of advancements in biologic wound healing treatment. To create high-quality wound care biologic solutions, major companies in the wound care biologics business spend a lot of money on research and development.

• The tri-layer skin graft Artacent AC, manufactured by the biologics business Tides Medical, was introduced in July 2022 to treat complicated or challenging-to-treat wounds.
• The department of U.S. defence awarded MIMEDX USD 4.6 million in May 2022 to investigate PURION-processed Dehydrated Human Amnion Chorion Membrane (DHACM) to advance the treatment of burns and wounds sustained during warfare.

Key Segments of Wound Care Biologics Industry Research

• By Product:

  • Biologic Skin Substitutes
  • Topical Agents

• By Wound Type:

  • Ulcers
  • Surgical & Traumatic Wounds
  • Burns

• By End User:

  • Hospitals
  • Ambulatory Surgical Centers
  • Burn Centers & Wound Clinics

• By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia & Oceania
  • MEA